期刊文献+

钙通道阻滞剂在降压治疗中的应用 被引量:10

Application of Calcium Channel Blockers in Hypertension Treatment
下载PDF
导出
摘要 钙通道阻滞剂通过阻滞动脉血管平滑肌细胞上的钙通道,降压疗效明确,适用于几乎所有类型的高血压患者。依据钙通道阻滞剂与动脉血管及心脏的亲和力不同,以及钙通道阻滞剂与钙离子通道亚型的亲和力不同,钙通道阻滞剂有效降压及全面心血管保护作用各有千秋。 By blocking the smooth muscle cell's calcium channel at arteries,calcium channel blockers( CCB) can reduce blood pressure effectively and reliably. According to the affinity of CCB on artery or heart,and on the basis of affection at subtype calcium channel,different CCBs have their own advantages on anti-hypertensive effects and cardiovascular protection.
作者 陈源源
出处 《心血管病学进展》 CAS 2015年第6期662-665,共4页 Advances in Cardiovascular Diseases
关键词 高血压 钙通道拮抗剂 钙离子通道亚型 心血管保护 hypertension calcium channel blockers subtype calcium channel cardiovascular protection
  • 相关文献

参考文献9

  • 1Hayashi K, Wakino S, Sugano N,et al. Ca^2 + channel subtypes and pharmacolo- gy in the kidney[J]. Cite Res,2007 ,100 :342-353.
  • 2薛全福,王振纲.钙通道不同分型与亚基和抗高血压药物的关系[J].中国药理学通报,2008,24(5):569-572. 被引量:13
  • 3刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93. 被引量:1220
  • 4Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Troatment ( INSIGHT ) [ J ]. Lancet ,2000,356:366-372.
  • 5Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patienta with symptomatic stable angina and hypertension : the ACTION trial [ J ]. J Hypertens,2005,23:641-648.
  • 6Poole-Wilson PA, Lubsea J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment ( LCTION trial) : randomized controlled trial [ J ]. Lancet, 2004,364 : 849-857.
  • 7Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the VALUE randomized trial [ J ]. Lancet,2004,363:2022-2031.
  • 8Dahloff B, Sever PS, Poulter NR,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) : a mul- tieentre randomised controlled trial[ J]. Lancet, 2005,366:895-906.
  • 9Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the avoi- ding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: a hypertensive population at higl cardiovascular risk [ J ]. Blood Press, 2007,16 : 13 -19.

二级参考文献37

共引文献1230

同被引文献80

引证文献10

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部